Such diagnosis is usually supported by evidence of CFTR dysfunction through identification of two CF-disease causing mutations, two abnormal sweat-Cl−tests (≥60 mEq/L), and/or distinctive transepithelial nasal potential difference (NPD) measurements [7], [8]. The gene discussed is CFTR; the disease is cystic fibrosis.